Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences

CAMBRIDGE, Mass., Jan. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas... Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, axonal degeneration
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news